Phaseline

Companies › Trevi Therapeutics

Trevi Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 4 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Gastroenterology, Other, Respiratory; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nalbuphine
Opioid receptors; mu/kappa/delta agonist
OPRK1, OPRD1, OPRM1Phase 3Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute …Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07435337NalbuphinePhase 4LaryngoscopyOtherMay 2026
NCT07271849NalbuphinePhase 4Postoperative Pain, AcuteNeurologyOct 2026
NCT07613801NalbuphinePhase 4Hip Fracture SurgeriesOtherNov 2026
NCT06037330NalbuphinePhase 4Acute Respiratory Distress SyndromeRespiratoryNov 2026
NCT06996561NalbuphinePhase 2CholecystectomyGastroenterologyJan 2027
NCT07868419NalbuphinePhase 3Idiopathic Pulmonary FibrosisRespiratoryAug 2027
NCT07671924NalbuphinePhase 2Refractory Chronic CoughOtherSep 2027
NCT07671911NalbuphinePhase 3Idiopathic Pulmonary FibrosisRespiratoryJun 2028

From the company's SEC filings

Cash and short-term investments of $299m on 2026-09-30; operating cash outflow about $72m a year; runway about 50 months at that burn, to Nov 2030; 4 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

OPRK1 (1) OPRD1 (1) OPRM1 (1)

Companies with the same targets

Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Johnson & Johnson (Janssen) Tioga Pharmaceuticals

Companies built like this

Ardelyx GRIN Therapeutics Adneuris Therapeutics AgelessRx Palvella Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.